Yayın:
A topography of immunotherapies against gastrointestinal malignancies

dc.contributor.authorDhasmana, Anupam
dc.contributor.authorDhasmana, Swati
dc.contributor.authorKotnala, Sudhir
dc.contributor.authorAnukriti
dc.contributor.authorKashyap, Vivek K.
dc.contributor.authorShaji, Poornima D.
dc.contributor.authorLaskar, Partha
dc.contributor.authorKhan, Sheema
dc.contributor.authorPellicano, Rinaldo
dc.contributor.authorFagoonee, Sharmila
dc.contributor.authorHaque, Shafiul
dc.contributor.authorYallapu, Murali M.
dc.contributor.authorChauhan, Subhash C.
dc.contributor.authorJaggi, Meena
dc.contributor.buuauthorHaque, Shafiul
dc.contributor.departmentBursa Uludağ Üniversitesi
dc.contributor.orcid0000-0002-2989-121X
dc.contributor.researcheridAAN-2946-2020
dc.date.accessioned2024-11-14T05:22:24Z
dc.date.available2024-11-14T05:22:24Z
dc.date.issued2022-03-01
dc.description.abstractGastrointestinal (GI) cancers are one of the leading causes of death worldwide. Although various approaches are implemented to improve the health condition of GI patients, none of the treatment protocols promise for eradicating cancer. However, a treatment mechanism against any kind of disease condition is already existing executing inside the human body. The 'immune system' is highly efficient to detect and destroy the unfavorable events of the body including tumor cells. The immune system can restrict the growth and proliferation of cancer. Cancer cells behave much smarter and adopt new mechanisms for hiding from the immune cells. Thus, cancer immunotherapy might play a decisive role to train the immune system against cancer. In this review, we have discussed the immunotherapy permitted for the treatment of GI cancers. We have discussed various methods and mechanisms, periodic development of cancer immunotherapies, approved biologicals, completed and ongoing clinical trials, role of various biopharmaceuticals, and epigenetic factors involved in GI cancer immunotherapies. (Cite this article as: Dhasmana A, Dhasmana S, Kotnala S, Anukriti, Kashyap VK, Shaji PD, et al. A topography of immunotherapies against gastrointestinal malignancies. Panminerva Med 2022;64:56-71.
dc.description.sponsorshipUnited States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Cancer Institute (NCI) - R01 CA210192 - R01 CA206069 - R01 CA204552
dc.identifier.doi10.23736/S0031-0808.21.04541-9
dc.identifier.eissn1827-1898
dc.identifier.endpage71
dc.identifier.issn0031-0808
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85128000431
dc.identifier.startpage56
dc.identifier.urihttps://doi.org/10.23736/S0031-0808.21.04541-9
dc.identifier.urihttps://www.minervamedica.it/en/journals/panminerva-medica/issue.php
dc.identifier.urihttps://hdl.handle.net/11452/47847
dc.identifier.volume64
dc.identifier.wos000777523600006
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherEdizioni Minerva Medica
dc.relation.journalPanminerva Medica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGrowth-factor receptor
dc.subjectMonoclonal-antibodies
dc.subjectCancer-immunotherapy
dc.subjectT-cells
dc.subjectTherapeutic strategy
dc.subjectMechanism
dc.subjectRna
dc.subjectChallenges
dc.subjectVaccines
dc.subjectGene
dc.subjectGastrointestinal neoplasms
dc.subjectNeoplasms
dc.subjectImmunotherapy
dc.subjectAntineoplastic agents
dc.subjectImmunological
dc.subjectCancer vaccines
dc.subjectMucins
dc.subjectUntranslated
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectMedicine, general & internal
dc.subjectGeneral & internal medicine
dc.titleA topography of immunotherapies against gastrointestinal malignancies
dc.typeReview
dspace.entity.typePublication
local.contributor.departmentBursa Uludağ Üniversitesi
local.indexed.atWOS
local.indexed.atScopus

Dosyalar